Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71


Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis.

Frederickson AM, Arndorfer S, Zhang I, Lorenzi M, Insinga R, Arunachalam A, Burke TA, Simon GR.

Immunotherapy. 2019 Apr;11(5):407-428. doi: 10.2217/imt-2018-0193. Epub 2019 Feb 4.


Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.


Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.

Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME.

J Clin Oncol. 2018 Feb 15:JCO2017756387. doi: 10.1200/JCO.2017.75.6387. [Epub ahead of print]


Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.

Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS.

Cancer. 2017 Sep 1;123(17):3367-3376. doi: 10.1002/cncr.30729. Epub 2017 May 18.


ALK: a tyrosine kinase target for cancer therapy.

Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR.

Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001115. doi: 10.1101/mcs.a001115. Review.


Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer.

Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH.

Clin Lung Cancer. 2017 Jul;18(4):e233-e241. doi: 10.1016/j.cllc.2016.11.002. Epub 2016 Nov 11.


Recent Advances in Immunotherapy in Metastatic NSCLC.

Bansal P, Osman D, Gan GN, Simon GR, Boumber Y.

Front Oncol. 2016 Nov 14;6:239. eCollection 2016. Review.


Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.

Bansal P, Osman D, Gan GN, Simon GR, Boumber Y.

Front Oncol. 2016 May 4;6:112. doi: 10.3389/fonc.2016.00112. eCollection 2016. Review.


A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.

Gray JE, Infante JR, Brail LH, Simon GR, Cooksey JF, Jones SF, Farrington DL, Yeo A, Jackson KA, Chow KH, Zamek-Gliszczynski MJ, Burris HA 3rd.

Invest New Drugs. 2015 Dec;33(6):1187-96. doi: 10.1007/s10637-015-0278-7. Epub 2015 Sep 25.


Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.

Oncoscience. 2014 Aug 7;1(8):522-528. eCollection 2014.


Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.

Campos-Gomez S, Lara-Guerra H, Routbort MJ, Lu X, Simon GR.

Int J Biol Markers. 2015 May 26;30(2):e254-7. doi: 10.5301/jbm.5000127.


Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.


nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.

Simon GR.

Clin Lung Cancer. 2014 Nov;15(6):391-7. doi: 10.1016/j.cllc.2014.07.003. Epub 2014 Aug 15. Review.


Molecular pathways and therapeutic targets in lung cancer.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R.

Oncotarget. 2014 Mar 30;5(6):1392-433. Review.


AAP principles concerning retail-based clinics.

Laughlin JJ, Simon GR, Baker C, Barden GA, Brown OW, Hardin A, Lessin HR, Meade K, Moore S, Rodgers CT; American Academy of Pediatrics Committee on Practice and Ambulatory Medicine.

Pediatrics. 2014 Mar;133(3):e794-7. doi: 10.1542/peds.2013-4080. Epub 2014 Feb 24.


Clinical practice guideline: acute otitis externa executive summary.

Rosenfeld RM, Schwartz SR, Cannon CR, Roland PS, Simon GR, Kumar KA, Huang WW, Haskell HW, Robertson PJ; American Academy of Otolaryngology--Head and Neck Surgery Foundation.

Otolaryngol Head Neck Surg. 2014 Feb;150(2):161-8. doi: 10.1177/0194599813517659.


Clinical practice guideline: acute otitis externa.

Rosenfeld RM, Schwartz SR, Cannon CR, Roland PS, Simon GR, Kumar KA, Huang WW, Haskell HW, Robertson PJ.

Otolaryngol Head Neck Surg. 2014 Feb;150(1 Suppl):S1-S24. doi: 10.1177/0194599813517083. Review. Erratum in: Otolaryngol Head Neck Surg. 2014 Mar;150(3):504. Otolaryngol Head Neck Surg. 2014 Mar;150(3):504.


A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

Simon GR, Somaiah N.

Clin Lung Cancer. 2014 Jan;15(1):21-51. doi: 10.1016/j.cllc.2013.11.009. Epub 2013 Nov 21.


Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery.

Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR.

Cancer Control. 2014 Jan;21(1):57-62.


EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.

Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II.

Clin Cancer Res. 2013 Dec 1;19(23):6556-65. doi: 10.1158/1078-0432.CCR-12-3946. Epub 2013 Oct 4.


Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A.

J Immunother. 2013 Oct;36(8):442-50. doi: 10.1097/CJI.0b013e3182a80237.


Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.

Simon GR, Manegold C, Barker SS, Treat JA, Visseren-Grul C, Obasaju C.

Clin Lung Cancer. 2013 Nov;14(6):601-8. doi: 10.1016/j.cllc.2013.06.001. Epub 2013 Aug 6. Review.


Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors.

Chakravarty S, Lai WC, Zou Y, Drabkin HA, Gemmill RM, Simon GR, Chin SH, Chen RT.

Biosens Bioelectron. 2013 May 15;43:50-5. doi: 10.1016/j.bios.2012.11.012. Epub 2012 Nov 27.


A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer.

Somaiah N, Simon NG, Simon GR.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S342-68. doi: 10.1097/JTO.0b013e318271c798. Review. No abstract available.


A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.

Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR.

Eur J Cancer. 2013 Mar;49(4):782-9. doi: 10.1016/j.ejca.2012.09.036. Epub 2012 Oct 22.


A novel classification of lung cancer into molecular subtypes.

West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R.

PLoS One. 2012;7(2):e31906. doi: 10.1371/journal.pone.0031906. Epub 2012 Feb 21.


Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection.

Tanner NT, Gomez M, Rainwater C, Nietert PJ, Simon GR, Green MR, Silvestri GA.

J Thorac Oncol. 2012 Feb;7(2):365-9. doi: 10.1097/JTO.0b013e31823a385f.


The role of molecular analyses in the era of personalized therapy for advanced NSCLC.

Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA.

Lung Cancer. 2012 May;76(2):131-7. doi: 10.1016/j.lungcan.2011.11.013. Epub 2011 Dec 15. Review.


Personalized lung cancer treatment based on molecular determinants.

Simon GR.

J S C Med Assoc. 2011 Oct;107(5):183-4. Review. No abstract available.


Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.


Molecular targeted agents and biologic therapies for lung cancer.

Somaiah N, Simon GR.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1758-85. doi: 10.1097/01.JTO.0000407557.30793.a6. No abstract available.


Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.

Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B.

Clin Cancer Res. 2011 Sep 15;17(18):6097-105. doi: 10.1158/1078-0432.CCR-11-0930. Epub 2011 Jul 26.


A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.

Simon GR, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-41. doi: 10.1007/s00280-011-1593-0. Epub 2011 Mar 23.


You just can't call it lung cancer anymore.

Simon GR, Silvestri GA.

J Thorac Oncol. 2011 Feb;6(2):239-40. doi: 10.1097/JTO.0b013e31820bf5b8. No abstract available.


Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).

Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R.

J Thorac Oncol. 2011 Jan;6(1):227-32. doi: 10.1097/JTO.0b013e3181fd789d.


Molecular targeted agents and biologic therapies for non-small cell lung cancer.

Somaiah N, Simon GR.

J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S434-54. doi: 10.1097/01.JTO.0000391362.10517.1f. No abstract available.


Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?

Aggarwal C, Somaiah N, Simon GR.

J Natl Compr Canc Netw. 2010 Jul;8(7):822-32. Review.


Non-small cell lung cancer.

Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC; NCCN Non-Small Cell Lung Cancer Panel Members.

J Natl Compr Canc Netw. 2010 Jul;8(7):740-801. Review. No abstract available.


Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope.

Simon GR.

J Clin Oncol. 2010 Feb 1;28(4):523-6. doi: 10.1200/JCO.2009.25.3773. Epub 2009 Dec 28. No abstract available.


Molecular targeted therapy in non-small cell lung cancer: an overview of available agents.

Somaiah N, Simon GR.

J Thorac Oncol. 2009 Nov;4(11 Suppl 3):S1046-56. doi: 10.1097/01.JTO.0000361747.56424.f7. No abstract available.


Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions.

Simon GR.

Curr Treat Options Oncol. 2008 Dec;9(4-6):300-12. doi: 10.1007/s11864-008-0075-z. Epub 2009 Mar 6. Review.


Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.

J Clin Oncol. 2008 Jul 20;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868.


Molecular analysis-based treatment strategies for non-small cell lung cancer.

Bepler G, Begum M, Simon GR.

Cancer Control. 2008 Apr;15(2):130-9.


Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.


Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G.

Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360.


Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.

Simon GR, Begum M, Bepler G.

Future Oncol. 2008 Feb;4(1):51-9. doi: 10.2217/14796694.4.1.51. Review.


Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Simon GR, Turrisi A; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):324S-339S.


Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).

Samson DJ, Seidenfeld J, Simon GR, Turrisi AT 3rd, Bonnell C, Ziegler KM, Aronson N; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):314S-323S. Review.


Supplemental Content

Loading ...
Support Center